BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy. It also develops Premvia, a HyStem hydrogel formulation for use in the treatment of age-related facial lipoatrophy, as well as for the management of wounds, including partial and full-thickness wounds, ulcers, tunneled/undermined wounds, surgical wounds, and burns; and ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis. In addition, the company through its subsidiary, AgeX Therapeutics, Inc., develops AGEX-BAT1 that consists of pluripotent stem cell-derived brown adipocytes for the treatment of type 2 diabetes; AGEX-VASC1, which consists of vascular progenitors targeting cardiac ischemia; and induced tissue regeneration, a systemic therapy for inducing the scar less regeneration of tissues. Further, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions. BioTime, Inc. was founded in 1990 and is based in Alameda, California.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryBiotechnology
SectorMedical
SymbolNYSEAMERICAN:BTX
CUSIP09066L10
Phone+1-510-5213390
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins828.55%
Return on Equity30.68%
Return on Assets27.02%
Miscellaneous
EmployeesN/A
Outstanding Shares126,880,000
Market Cap$338.75 million
BioTime (NYSEAMERICAN:BTX) Frequently Asked Questions
What is BioTime's stock symbol?
BioTime trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX."
How were BioTime's earnings last quarter?
BioTime, Inc. (NYSEAMERICAN:BTX) issued its quarterly earnings results on Thursday, August, 2nd. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.03. The biotechnology company earned $2.55 million during the quarter, compared to analysts' expectations of $0.33 million. BioTime had a net margin of 828.55% and a return on equity of 30.68%. View BioTime's Earnings History.
When is BioTime's next earnings date?
What price target have analysts set for BTX?
1 equities research analysts have issued 12-month target prices for BioTime's shares. Their predictions range from $8.00 to $8.00. On average, they expect BioTime's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 234.7% from the stock's current price. View Analyst Price Targets for BioTime.
What is the consensus analysts' recommendation for BioTime?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTime in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTime.
Are investors shorting BioTime?
BioTime saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 13,153,727 shares, an increase of 0.5% from the August 15th total of 13,086,517 shares. Based on an average daily volume of 270,917 shares, the short-interest ratio is presently 48.6 days. Approximately 10.5% of the shares of the company are sold short. View BioTime's Current Options Chain.
Who are some of BioTime's key competitors?
Some companies that are related to BioTime include Biotest (BIO), ProMetic Life Sciences (PLI), Genfit (GNFTF), Mesoblast (MSB), Theratechnologies (TH), Mesoblast (MEOBF), Emerald Health Therapeutics (EMH), Starpharma (SPL), MediGene (MDG1), Oxford BioMedica (OXB), Resverlogix (RVX), 22nd Century Group (XXII), Protalix Biotherapeutics (PLX), Neptune Technologies & Bioressources (NEPT) and Monash IVF Group (MVF).
Who are BioTime's key executives?
BioTime's management team includes the folowing people:
- Dr. Michael D. West, Co-CEO & Director (Age 65)
- Mr. Aditya P. Mohanty, Co-CEO, Pres & Director (Age 51)
- Mr. Russell L. Skibsted, Chief Financial Officer (Age 59)
- Dr. Stephana E. Patton, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 47)
- Mr. William Annett, Pres & CEO of OncoCyte Corp. (Age 64)
Has BioTime been receiving favorable news coverage?
Press coverage about BTX stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioTime earned a media and rumor sentiment score of 0.18 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for BioTime.
Who are BioTime's major shareholders?
BioTime's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Northern Trust Corp (0.80%), Bank of New York Mellon Corp (0.59%), Bank of New York Mellon Corp (0.59%) and Renaissance Technologies LLC (0.11%). Company insiders that own BioTime stock include Aditya P Mohanty, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Institutional Ownership Trends for BioTime.
Which institutional investors are selling BioTime stock?
Which institutional investors are buying BioTime stock?
BTX stock was bought by a variety of institutional investors in the last quarter, including Northern Trust Corp, Bank of New York Mellon Corp and Bank of New York Mellon Corp. Company insiders that have bought BioTime stock in the last two years include Aditya P Mohanty, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Insider Buying and Selling for BioTime.
How do I buy shares of BioTime?
Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioTime's stock price today?
One share of BTX stock can currently be purchased for approximately $2.39.
How big of a company is BioTime?
BioTime has a market capitalization of $338.75 million.
How can I contact BioTime?
BioTime's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-5213390.
MarketBeat Community Rating for BioTime (NYSEAMERICAN BTX)
MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote "Outperform" if you believe BTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
